ORMP (Oramed Pharmaceuticals) Current Accrued Expense: $1.86 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ORMP Oramed Pharmaceuticals Inc ORMP
32 GF Score
Price $4.79
! 5 Warning Signs
View Full Analysis

What is Oramed Pharmaceuticals Current Accrued Expense?

Oramed Pharmaceuticals ORMP 32 Current Accrued Expense is $1.86 Mil as of Jun. 2026. GuruFocus rates ORMP with a GF Score™ of 32/100. The stock has 5 warning signs investors should review.

Oramed Pharmaceuticals's Current Accrued Expense for the quarter that ended in Jun. 2026 was $1.86 Mil.

Oramed Pharmaceuticals's quarterly Current Accrued Expense declined from Dec. 2025 ($2.47 Mil) to Mar. 2026 ($1.88 Mil) and declined from Mar. 2026 ($1.88 Mil) to Jun. 2026 ($1.86 Mil).

Oramed Pharmaceuticals's annual Current Accrued Expense increased from Dec. 2023 ($1.06 Mil) to Dec. 2024 ($1.15 Mil) and increased from Dec. 2024 ($1.15 Mil) to Dec. 2025 ($2.47 Mil).

Oramed Pharmaceuticals Current Accrued Expense Related Terms

Oramed Pharmaceuticals Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Oramed Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oramed Pharmaceuticals Current Accrued Expense Chart

Oramed Pharmaceuticals Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.19 1.98 1.06 1.15 2.47

Oramed Pharmaceuticals Quarterly Data
Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.10 0.82 2.47 1.88 1.86
ORMP
32GF Score
Oramed Pharmaceuticals Inc ORMP
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oramed Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $1.86 Mil mean?
Oramed Pharmaceuticals (ORMP) has a Current Accrued Expense of $1.86 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Oramed Pharmaceuticals and its competitors.
Is Oramed Pharmaceuticals' Current Accrued Expense too high?
Oramed Pharmaceuticals' current Current Accrued Expense is $1.86 Mil. Overall, Oramed Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Oramed Pharmaceuticals' Current Accrued Expense compare to CAMP and PYXS?
Oramed Pharmaceuticals' Current Accrued Expense of $1.86 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Oramed Pharmaceuticals and its competitors. Oramed Pharmaceuticals's current Current Accrued Expense is $1.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oramed Pharmaceuticals stock overvalued right now?
Oramed Pharmaceuticals (ORMP) has a current Current Accrued Expense of $1.86 Mil. The current Current Accrued Expense is $1.86 Mil. Oramed Pharmaceuticals' overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Oramed Pharmaceuticals (ORMP), the current Current Accrued Expense is $1.86 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oramed Pharmaceuticals Business Description

Other Exchanges ORMP:IsraelOJU1:Germany
Address 1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
32GF Score

Get the complete analysis for ORMP

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.79
Price